IMM-1-104: Topline data from the Phase 1 portion of the Phase 1/2a clinical trial expected in March 2024. The update is expected to include data on the primary and secondary endpoints of the Phase 1 portion of the Phase 1/2a study, as well as PD, ctDNA, and initial clinical activity data. First patient expected to be dosed in the Phase 2a portion of the Phase 1/2a trial in March 2024. Initial data from multiple Phase 2a arms expected in 2024. Additional trial updates expected on a periodic basis. IMM-6-415: First patient expected to be dosed in the Phase 1 portion of the Phase 1/2a trial in March 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IMRX:
- Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
- Immuneering receives FDA Fast Track designation for IMM-1-104
- Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
- Immuneering Announces Participation in February Investor Conferences
